Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
spooky but there is lol.............
ime with virgin,i was told you just change to ski or someone else and you get a new pc/ip adress.............
you still not found them have you........lol
river/lake/pond /sea.....
av u seen jonc,i avnt?..
thatz the one..lol..
how did he bypass the ip adresss for so long then,i guess admin av some kind of technology to check,not sure about this techno stuff... chiffa turned up on wsg the other week and got zapped after 10 minutes.....
you was talking to nettley on the bbr board the other week,he played loads of u tube and sed he came off adv...had a name like atm or something like that...
Lego it was R Dutch Shell A Share Price (0LN9)
dont know,no one az a rude posting style like him/her..quite unique if you ask most peeps...everyone seems to av a posting style..imo...especially lego....
lego,jange?getting dizzy with this board hopping..lol... windsor,yeah i thought he was jck,he liked the same kind of music and posted on bem/xel.which jc posted on... top toad....
Top man imho.........
hese not rude enough.... or plays punk music......
just got in,but reading around all day,well most of it..............................
just someone that was about years ago,that dissappeared then turned up last year... not 100% sure tho,just somethings he said that only hede know...... a gud week 4ya then..?...
first five postsssssss
Positive Points: The results materialised at the upper end of analyst forecasts. The board expects full-year 2013 revenues to be near 2012 levels on a constant currency basis. Emerging Market sales accounted for approximately 20% of pharmaceutical sales in the fourth quarter. Management previously emphasised its strategy of executing on its core business, expanding geographically in high-growth markets, extending its complementary businesses and focussing at managing costs while investing for growth. Merck has been cutting costs as part of an effort to soften the blow from increased generic competition.. Unlike some rivals, the company is not totally dependent on drug sales. Sales for both its Consumer Care and Animal Health businesses both increased in the final quarter - plus 9% and 3% respectively. The company previously highlighted that it plans to seek US regulatory approval by the end of 2013 for its insomnia drug suvorexant, its osteoporosis treatment odanacatib, and cholesterol drug tredaptive. A dividend yield of over 3% remains relatively attractive in the current low interest rate environment.
Negative Points: Worldwide sales of SINGULAIR, its once-a-day oral medicine for the chronic treatment of asthma, declined by 67%. Its European patent will expire later this month. Governments around the world continue to try and reduce health spending budgets. Currency movements impacted negatively over the year. The pharmaceutical industry is exposed to political risk, litigation, product development risk, regulatory risk, and pricing pressures.
Financial Highlights: Fourth-quarter pharmaceutical sales declined by 6% to $10.1 billion Full-year pharmaceutical sales declined by 2% to $40.6 billion, including a 3% negative currency impact A Q4 profit of $1.4 billion or 46 US cents per share was reported, down from $1.51 billion or 49 cents per share in Q4 2011
Fourth quarter/Full year results: Like rivals, the announcement continued to see the company battling against the loss of drug patents, with generic competition hitting the market. Total fourth-quarter pharmaceutical sales declined by 6% to $10.1 billion. Worldwide sales of SINGULAIR, a once-a-day oral medicine for the chronic treatment of asthma, declined by 67%. Sales for the asthma drug fell by $932 million, or 97% in the US during the quarter, following the loss of its patent back in August (2012). The patent will expire in major European markets later this month. Nonetheless, sales for other drugs such as its diabetes medicine helped to compensate, growing by 18% to $1.6 billion in the final quarter, whilst broader drug sales to the Emerging Markets grew by 9%. Emerging Market sales accounted for approximately 20% of pharmaceutical sales in the fourth quarter. Furthermore, global sales for its Consumer Care division expanded by 9% compared to Q4 2011, aided by sales of Coppertone and Dr Scholl's footcare products. In all, and aided by a dividend yield of over 3% (as of 01Feb2013 - not guaranteed), market consensus opinion currently denotes a buy.